0
0
New Delhi, June 19, 2025 – The National Institute of Virology (NIV) is making significant strides in the fight against several life-threatening viruses, expanding its focus far beyond dengue. India’s first indigenous dengue vaccine has reached the final phase of human trials, marking a crucial milestone in the battle against the mosquito-borne illness.
NIV is also developing vaccines and diagnostic tools for other high-risk viruses, aiming to reduce the country’s dependence on imported technology and bolster epidemic preparedness. Among the targets is the Kyasanur Forest Disease (KFD) virus, which causes severe fever and is prevalent in Karnataka and surrounding forested regions. The KFD vaccine is now in an advanced stage of development.
Additionally, NIV is working on a vaccine for the highly lethal Nipah virus, using cutting-edge monoclonal antibody technology. The Crimean-Congo Hemorrhagic Fever (CCHF) virus, another zoonotic pathogen, is also under the institute’s radar for vaccine development.
These efforts are part of a broader strategy to strengthen India’s public health infrastructure and readiness against emerging infectious diseases. By advancing indigenous research and manufacturing, NIV is positioning India as a key player in global health security.
Disclaimer:
This news article is based on information sourced from MangaloreToday and related reports as of June 19, 2025. While every effort has been made to ensure accuracy, readers are advised to refer to official statements or updates from the National Institute of Virology for the latest developments. The article does not constitute medical advice.
